SAN DIEGO, Oct. 28, 2019 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced they will be presenting new scientific data at the American College of Rheumatology’s (ACR/ARHP) Annual Meeting being held November 9-12, 2019 in Atlanta, GA.
“We are very pleased to have nine abstracts accepted including 5 posters and 4 podium presentations at the ACR/ARHP Annual Conference,” shared Thierry Dervieux, Chief Scientific Officer at Exagen. “Not only is this the greatest number of abstracts we have ever presented, but it also reflects the most diverse representation of the laboratory science we are investigating at Exagen. The topics we will be reporting on include clinical utility and clinical validity of the AVISE Lupus test, novel biomarkers in rheumatoid arthritis and lupus, and therapeutic optimization of some of the most widely used drugs in rheumatology.”A list of accepted abstracts along with links is included below.Nov 10thPoster Presentation I Presented by Rosalind Ramsey-Goldman, MD I Abstract: 669
Title: Complement Activation in Probable Systemic Lupus Erythematosus (pSLE) May Predict Progression to SLE Defined by Fulfillment of ACR Classification Criteria
Session Title: SLE – Clinical Poster II: ComorbiditiesPodium Presentation | Presented by Daniel J. Wallace, MD | Abstract: 942
Title: A Randomized Prospective Trial to Assess the Clinical Utility of Multianalyte Assay with Complement Activation Products in Diagnosing Systemic Lupus Erythematosus
Session Title: SLE–Clinical III: Clinical Trials IINov 11thPoster Presentation I Presented by Michelle Petri, MD I Abstract: 1602
Title: Persistency in Platelet C4d and Thrombosis Risk Score Associated with Thrombosis in Systemic Lupus Erythematosus
Session Title: SLE – Clinical Poster I: Epidemiology & Pathology
Bay Street News